Abstract
For decades, researchers have used the concepts of rate of change and differential equations to model and forecast neoplastic processes. This expressive mathematical apparatus brought significant insights in oncology by describing the unregulated proliferation and host interactions of cancer cells, as well as their response to treatments. Now, these theories have been given a new life and found new applications. With the advent of routine cancer genome sequencing and the resulting abundance of data, oncology now builds an “arsenal” of new modeling and analysis tools. Models describing the governing physical laws of tumor–host–drug interactions can be now challenged with biological data to make predictions about cancer progression. Our study joins the efforts of the mathematical and computational oncology community by introducing a novel machine learning system for data-driven discovery of mathematical and physical relations in oncology. The system utilizes computational mechanisms such as competition, cooperation, and adaptation in neural networks to simultaneously learn the statistics and the governing relations between multiple clinical data covariates. Targeting an easy adoption in clinical oncology, the solutions of our system reveal human-understandable properties and features hidden in the data. As our experiments demonstrate, our system can describe nonlinear conservation laws in cancer kinetics and growth curves, symmetries in tumor’s phenotypic staging transitions, the preoperative spatial tumor distribution, and up to the nonlinear intracellular and extracellular pharmacokinetics of neoadjuvant therapies. The primary goal of our work is to enhance or improve the mechanistic understanding of cancer dynamics by exploiting heterogeneous clinical data. We demonstrate through multiple instantiations that our system is extracting an accurate human-understandable representation of the underlying dynamics of physical interactions central to typical oncology problems. Our results and evaluation demonstrate that, using simple—yet powerful—computational mechanisms, such a machine learning system can support clinical decision-making. To this end, our system is a representative tool of the field of mathematical and computational oncology and offers a bridge between the data, the modeler, the data scientist, and the practicing clinician.
1 Introduction
The dynamics governing cancer initiation, development, and response to treatment are informed by quantitative measurements. These measurements carry details about the physics of the underlying processes, such as tumor growth, tumor–host cell encounters, and drug transport. Be it through mathematical modeling and patient-specific treatment trajectories—as in the excellent work of —through tumor’s mechanopathology—systematically described by —or through hybrid modeling frameworks of tumor development and treatment—identified by —capturing such processes from data can substantially improve predictions about cancer progression.
Machine learning algorithms are now leveraging automatic discovery of physics principles and governing mathematical relations for such improved predictions. Proof stands the proliferating body of such research—for representative results, see the works of ), ), ), and ). However, the naive application of such algorithms is insufficient to infer physical laws underlying cancer progression. Simply positing a physical law or mathematical relation from data is useless without simultaneously proposing an accompanying ground truth to account for the inevitable mismatch between model and observations, as demonstrated in the work of ).
Such a problem is even more important in clinical oncology where, in order to understand the links between the physics of cancer and signaling pathways in cancer biology, we need to describe the fundamental physical principles shared by most, if not all, tumors, as proposed by . Here, mathematical models of the physical mechanisms and corresponding tumor physical hallmarks complement the heterogeneity of the experimental observations. Such a constellation is typically validated through in vivo and in vitro model systems where the simultaneous identification of both the structure and parameters of the dynamical system describing tumor–host interactions is performed ().
Given the multidimensional nature of this system identification process, some concepts involved are nonintuitive and require deep and broad understanding of both the physical and biological aspects of cancer. To circumvent this, combining mechanistic modeling and machine learning is a promising approach with high potential for clinical translation. For instance, in a bottom-up approach, fusing cell-line tumor growth curve learning from heterogeneous data (i.e., caliper, imaging, microscopy) and unsupervised extraction of cytostatic pharmacokinetics, the study by introduced a novel pipeline for patient-tailored neoadjuvant therapy planning. In another relevant study, used machine learning to extract model parameters from high-dimensional baseline data (demographic, clinical, pathological molecular) and used mixed-effects theory to combine it with mechanistic models based on longitudinal data (e.g., tumor size measurements, pharmacokinetics, seric biomarkers, and circulating DNA) for treatment individualization.
Yet, despite the recent advances in mathematical and computational oncology, there are only a few systems trying to offer a human-understandable solution, or the steps to reach it—the most relevant are the studies by and . But, such systems lack a rigorous and accessible description of the physical cancer traits assisting their clinical predictions. Our study advocates the improvement of mechanistic modeling with the help of machine learning. Our thesis goes beyond measurements-informed biophysical processes models, as described by , and toward human-understandable personalized disease evolution and therapy profiles learned from data, as foreseen by .
1.1 Study Focus
The purpose of this study is to introduce a system (and a framework) capable of learning human-understandable mathematical and physical relations from heterogeneous oncology data for patient-centered clinical decision support. To demonstrate the versatility of the system, we introduce multiple of its instantiations, in an end-to-end fashion (i.e., from cancer initiation to treatment outcome) for predictions based on available clinical datasets
1:
• learning initiation patterns of preinvasive breast cancer (i.e., ductal carcinoma in situ [DCIS]) from histopathology and morphology data available from the studies by ), ), ),and ;
• learning unperturbed tumor growth curves within and between cancer types (i.e., breast, lung, leukemia) from imaging, microscopy, and caliper data available from the studies by ) and );
• extracting tumor phenotypic stage transitions from three cell lines of breast cancer using imaging, immunohistochemistry, and histopathology data available from the studies by ), ), ), and ;
• simultaneously extracting the drug-perturbed tumor growth and drug pharmacokinetics for neoadjuvant/adjuvant therapy sequencing using data available from the studies by ), ), and ;
• predicting tumor growth/recession (i.e., estimating tumor volume after each chemotherapy cycle under various chemotherapy regimens administered to breast cancer patients, using real-world patient data available from the study by as well as cell lines studies from ), ), ),and .
In each of the instantiations, we use the same computational substrate (i.e., no specific task parametrization) and compare the performance of our system against state-of-the-art systems capable of extracting governing equations from heterogeneous oncology data from , , , and , respectively. The analysis focuses on (1) the accuracy of the systems in the learned mathematical and physical relations among various covariates, (2) the ability to embed more data and mechanistic models, and (3) the ability to provide a human-understandable solution and the processing steps to obtain that solution.
1.2 Study Motivation
In clinical practice, patient tumors are typically described across multiple dimensions from (1) high-dimensional heterogeneous data (e.g., demographic, clinical, pathological, molecular), and (2) longitudinal data (e.g., tumor size measurements, pharmacokinetics, immune screening, biomarkers), to (3) time-to-event data (e.g., progression-free or overall survival analysis), and, in the last years, (4) genetic sequencing that determine the genetic mutations driving their cancer. With this information, the clinical oncologist may tailor treatment to the patient’s specific cancer.
But, despite the variety of such rich patient data available, tumor growth data, describing the dynamics of cancer development, from initiation to metastasis has some peculiarities. These features motivated the study and the approach proposed by our system. To summarize, tumor growth data:
• is typically small, with only a few data points measured, typically, at days-level resolution ();
• is unevenly sampled, with irregular spacing among tumor size/volume observations ();
• has high variability between and within tumor types () and type of treatment ().
• is heterogeneous and sometimes expensive or difficult to obtain (e.g., biomarkers, functional magnetic resonance imaging (), fluorescence imaging (), flow cytometry, or calipers ().
• determines cancer treatment planning, for instance, adjuvant versus neoadjuvant chemotherapy ().
Using unsupervised learning, our system seeks to overcome these limitations and provide a human-understandable representation of the mathematical and physical relations describing tumor growth, its phenotype, and, finally, its interaction with chemotherapeutic drugs. The system exploits the temporal evolution of the processes describing growth data along with their distribution in order to reach superior accuracy and versatility on various clinical in vitro tumor datasets.
2 Materials and Methods
In the current section, we introduce our system through the lens of practical examples of discovering mathematical and physical relations describing tumor–host–drug dynamics. We begin by introducing the basic computational framework as well as the various configurations in which the system can be used. The second part is dedicated to introducing relevant state-of-the-art approaches used in our comparative experimental evaluation.
2.1 System Basics
Physical interactions of cancer cells with their environment (e.g., local tissue, immune cells, drugs) determine the physical characteristics of tumors through distinct and interconnected mechanisms. For instance, cellular proliferation and its inherent abnormal growth patterns lead to increased solid stress (). Subsequently, cell contraction and cellular matrix deposition modify the architecture of the surrounding tissue, which can additionally react to drugs () modulating the stiffness () and interstitial fluid pressure (). But such physical characteristics also interact among each other initiating complex dynamics, as demonstrated in .
Our system can capture such complex dynamics through a network-based paradigm for modeling, computation, and prediction. It can extract the mathematical description of the interactions exhibited by multiple entities (e.g., tumor, host cells, cytostatic drugs) for producing informed predictions. For guiding the reader, we present a simple, biologically grounded example in Figure 1.
FIGURE 1
In this example, our system learns simultaneously the power-law tumor growth under immune escape () and the nonlinear potentiation–inhibition model of natural killer (NK) cells–tumor interactions (), while exhibiting the known overlapping cytotoxic T lymphocytes (CTLs)–NK cell mutual linear regulation pattern (). As shown in Figure 1, our system offers the means to learn the mathematical relations governing the physical tumor–immune interactions, without supervision, from available clinical data (Figure 1—input data relations and learned and decoded relations). Furthermore, the system can infer unavailable (i.e., expensive to measure) physical quantities (i.e., after learning/training) in order to make predictions on the effects of modifying the pattern of interactions among the tumor and the immune system. For instance, by not feeding the system with the innate immune response (i.e., the NK cells dynamics), the system infers, based on the CTL–NK cell interaction pattern and the tumor growth pattern, a plausible tumor–NK cell mathematical relation in agreement with observations (Figure 1B, squared root nonlinearity).
Basically, our system acts as constraint satisfaction network converging to a global consensus given local (i.e., the impact of the measured data) and global dynamics of the physics governing the interactions (see the clear patterns depicting the mathematical models of interaction in Figure 1). The networked structure allows the system to easily interconnect multiple data quantities measuring different biological components () or a different granularity of representation of the underlying interaction physics ().
2.2 Computational Substrate
The core element of our study is an unsupervised machine learning system based on Self-Organizing Maps (SOMs) and Hebbian learning (HL) . The two components are used in concert to represent and extract the underlying relations among correlated data. In order to introduce the computational steps followed by our system, we provide a simple example in Figure 2. Here, we feed the system with data from a cubic growth law (third power-law) describing the effect of drug dose density over 150 weeks of adjuvant chemotherapy in breast cancer (data from ). The two data sources (i.e., the cancer cell number and the irregular measurement index over the weeks) follow a cubic dependency (cmp. Figure 2A). Before being presented the data, our system has no prior information about the data distribution and its generating process (or model). The system learns the underlying (i.e., hidden) mathematical relation directly from the pairs of input data without supervision.
FIGURE 2
The input SOMs (i.e., one-dimensional [1-D] lattice networks with N neurons) extract the probability distribution of the incoming data, depicted in Figure 2A, and encode samples in a distributed activity pattern, as shown in Figure 2B. This activity pattern is generated such that the closest preferred value of a SOM neuron to the input will be strongly activated and will decay, proportional with distance, for neighboring units. This process is fundamentally benefiting from the quantization capability of SOM. The tasks we solve in this work have low dimensionality, basically allowing a 1-D SOM to provide well-behaved distributed representations. 1-D SOMs are proven mathematically to converge and handling boundary effects. For higher-dimensional data, our system can be coupled with a reduction technique (i.e., principal component analysis, t-Distributed Stochastic Neighbor Embedding) to reduce data to 1-D time series, without a large penalty in complexity. In addition, this process is extended with a dimension corresponding to the latent representation of network resource allocation (i.e., number of neurons allocated to represent the input data space). After learning, the SOMs specialize to represent a certain (preferred) value in the input data space and learn its probability distribution, by updating its tuning curves shape.
Practically, given an input value sp(k) from one time series at time step k, the network follows the processing stages in Figure 3. For each ith neuron in the pth input SOM, with preferred value and tuning curve size , the generated neural activation is given by
FIGURE 3

Detailed computational steps of our system, instantiated for tumor growth learning given the observed number of cells and the measurement index data from
The most active (i.e., competition winning) neuron of the pth population, bp(k), is the one that has the highest activation given the time series data point at time k
The competition for highest activation (in representing the input) in the SOM is followed by a cooperation process that captures the input space distribution. More precisely, given the winning neuron, bp(k), the cooperation kernel,allows neighboring neurons in the network (i.e., found at position ri in the network) to precisely represent the input data point given their location in the neighborhood σ(k) of the winning neuron. The topological neighborhood width σ(k) decays in time, to avoid artifacts (e.g., twists) in the SOM. The kernel in Eq. 3 is chosen such that adjacent neurons in the network specialize on adjacent areas in the input space, by “pulling” the input weights (i.e., preferred values) of the neurons closer to the input data point,
This process updates the tuning curves width given the spatial location of the neuron in the network, the distance to the input data point, the cooperation kernel size, and a decaying learning rate α(k),
To illustrate these mechanisms, we consider the learned tuning curves shapes for five neurons in the input SOMs (i.e., neurons 1, 6, 13, 40, 45) encoding the breast cancer cubic tumor growth law, depicted in Figure 4. We observe that higher input probability distributions are represented by dense and sharp tuning curves (e.g., neuron 1, 6, 13 in SOM1), whereas lower or uniform probability distributions are represented by more sparse and wide-tuning curves (e.g., neuron 40, 45 in SOM1).
FIGURE 4

Extracted mathematical relation describing the growth law and data statistics for the experimental observations in Figure 2A depicting a cubic breast cancer tumor growth law among number of cells and irregular measurement over 150 weeks from
This way, the system optimally allocates neurons such that a higher amount of neurons represent areas in the input space, which need a finer resolution, and a lower amount for more coarsely represented input space areas. Neurons in the two SOMs are then linked by a fully (all-to-all) connected matrix of synaptic connections, where the weights are computed using HL. The connections between uncorrelated (or weakly correlated) neurons in each SOM (i.e., wcross) are suppressed (i.e., darker color), whereas correlated neuron connections are enhanced (i.e., brighter color), as depicted in Figure 3. Each connection weight between neurons i, j in the input SOMs is updated with an HL rule as follows:whereis an exponential decay (i.e., momentum), and η(k), β(k) are monotonic (inverse-time) decaying functions. HL ensures a weight increase for correlated activation patterns and a weight decrease for anticorrelated activation patterns. The Hebbian weight matrix encodes the coactivation patterns between the input SOMs, as shown in Figure 2B, and, eventually, the learned mathematical relation given the data, as shown in Figure 4. Such a representation, as shown in Figure 4, demonstrates the human-understandable output of our system that employs powerful, yet simple and transparent, processing principles, as depicted in Figure 3.
Input SOM self-organization and Hebbian correlation learning operate at the same time in order to refine both the input data representation and the extracted mathematical relation. This is visible in the encoding and the decoding functions where the input activations a are projected through the input weights win (Eq. 1) to the Hebbian matrix and then decoded through the wcross correlation weights (Eq. 8).
In order to recover the real-world value from the network, we use a decoding mechanism based on (self-learned) bounds of the input data space. The input data space bounds are obtained as minimum and maximum of a cost function of the distance between the current preferred value of the winning neuron (i.e., the value in the input which is closest [in Euclidian space] to the weight vector of the neuron) and the input data point in the SOM (i.e., using Brent’s optimization
2.3 Comparable Systems
In this section, we briefly introduce four state-of-the-art approaches that we comparatively evaluated against our system. Ranging from statistical methods, to machine learning, and up to deep learning (DL), the selected systems were designed to extract governing equations from the data.
Cook et al. The system of
Weber and Wermter. Using a different neurally inspired substrate, the system of
Mandal and Cichocki. Going away from biological inspiration, the system of
Champion et al. As DL is becoming a routine tool for data discovery, as shown in the recent work of
3 Experimental Setup and Results
In order to evaluate our data-driven approach to learn mathematical and physical relations from heterogeneous oncology data, we introduce the five instantiations and their data briefly introduced in the Study Focus section.
3.1 Datasets
In our experiments, we used publicly available tumor growth, pharmacokinetics, and chemotherapy regimens datasets (Table 1), with in vitro or in vivo clinical tumor volume measurements, for breast cancer (datasets 1, 2, 5, 6, 7) and other cancers (e.g., lung, leukemia—datasets 3 and 4, respectively). This choice is to probe and demonstrate transfer capabilities of the system to tumor growth patterns induced by different cancer types. The choice of the dataset for each of the experiments was determined by the actual task we wanted to demonstrate. For instance, for demonstrating the capability to predict preinvasive cancer volume, we used the DCIS dataset. For the between-cancer predictions, we used four (i.e., two breast and two nonbreast) out of the whole seven datasets, whereas for the within-cancer-type analysis, we only looked at the breast cancer growth prediction (i.e., four datasets). For the in vivo experiment, we only considered the I-SPY2 trial data.
TABLE 1
| Experimental dataset setup | ||||
|---|---|---|---|---|
| Dataset | Cancer type | Data type | Data points | Data freq. |
| 1 | Breast1 (MDA-MB-231 cell line) | Fluorescence imaging | 7 | 2×/week |
| 2 | Breast2 (MDA-MB-435 cell line) | Digital caliper | 14 | 2×/week |
| 3 | Lung3 | Caliper | 10 | 7×/week |
| 4 | Leukemia4 | Microscopy | 23 | 7×/week |
| 5 | Breast5 (MCF-7 cell line) | Microscopic imaging | 8 | 1×/week |
| 6 | Breast6 (LM2-4LUC + cell line) | Digital caliper | 10 | 3×/week |
| 7 | Breast7 (stage 2/3 cancers) | Functional magnetic resonance imaging | 5 | 1×/week |
| 8 | Breast8 (ductal carcinoma in situ) | Histopathology | 5 | 1×/week |
Description of the datasets used in the experiments.
Dataset from the study by
2Dataset from the study by
3Dataset from the study by
4Dataset from the study by
5Dataset from the study by
7Dataset from the study by
8Dataset from the study by
It is important to note that tumor cancer types are staged based on the size and spread of tumors, basically their volume. However, because leukemia occurs in the developing blood cells in the bone marrow, its staging is different from solid tumors. In order to emphasize the versatility of the evaluated systems, for the leukemia datasets, we used experiments that monitored human leukemic cell engraftment over time by monitoring tumor volume in scaffolds (
3.2 Procedures
In order to train the different approaches we considered in our study, basically the datasets were preprocessed to represent two-dimensional dynamics, namely, tumor growth or drug concentration evolution and irregular time evolution, respectively. Each of the two time series was directly encoded in neural distributed neural populations for the work by Cook et al., Weber et al., and our approach, whereas the approaches of Mandal et al. and Champion et al. fused the time series in a single input vector. For the training part, the work by Mandal et al. used alternating conditional expectation algorithm to calculate optimal transformations by fast boxcar averaging the rank-ordered data, whereas the Champion et al. approach used backpropagation. The neurally inspired approaches in Cook et al., Weber et al., and our system used HL, Sigma-Pi (Sum-Product) learning, and a combination of competition and cooperation for correlation learning, respectively. Finally, for inference, we used the systems resulting from the training phase (without modification) for one pass (forward pass) of unseen data through the system (i.e., basically accounting to a series of linear algebra operations).
Our system in all of our experiments, data depicting tumor growth, pharmacokinetics, and chemotherapy regimens are fed to our system, which encodes each time series in the SOMs and learns the underlying relations in the Hebbian matrix. The SOMs are responsible for bringing the time series in the same latent representation space where they can interact (i.e., through their internal correlation). Throughout the experiments, each of the SOM has
N= 100 neurons, the Hebbian connection matrix has size
N×
N, and parametrization is done as follows:
α= [0.01, 0.1] decaying,
η= 0.9,
decaying following an inverse time law. The training procedure of our system follows the next steps:
• normalize the input dataset;
• set up condition to reach relaxed state (i.e., no more fluctuations [Δϵ] in the SOM neural activation and Hebbian matrix);
• for each new data item, go through the pairs of neural populations (i.e., SOMs) and compute activation;
• for cross-connection among SOMs compute the Hebbian matrix entries;
• after convergence (i.e., reached Δϵ), the system comprises the learned relation encoded in the matrix;
The testing procedure of our system follows the next steps:
• decode the encoded relation from the Hebbian matrix;
• denormalize data to match the original input space;
• compare with ground truth.
An important aspect is that for our system, after convergence (i.e., reaching an Δϵ of changes in weights), the content of the Hebbian matrix is decoded. This amounts to a process in which the (now) static layout of values in the matrix actually depicts the underlying function y = f (x). Our system is basically updating the weights and shapes of the tuning curves (i.e., preferred values) of the SOMs and the cross-SOM Hebbian weights in the training process. After training, for inference and testing, the decoded function (i.e., using Brent’s derivative-free optimization method) accounts for a typical regression neural network for which cross-validation is applied. More precisely, we ran a fourfold cross-validation for each dataset.
Cook et al. For the neural network system proposed by
Weber et al. For the neural network system proposed by
Mandal et al. For the CCA-based system proposed by
. For our DL implementation, we used the system of
as a reference. We then modified the structure to accommodate the peculiarities of the clinical data. In all the experiments, the DL system contained hidden layers of size 128 neurons, trained for 100 epochs, with a mini-batch size of 1, and 50% augmentation percentage. The full codebase is provided, along the other systems reference implementations, on GitLab. Another important implementation aspect is that we use a combination of SVM and DL approaches. While SVM can work with a limited amount of data, DL models tend to perform worse when big data are not available. Therefore, we test multiple approaches to artificially augment the training data:
• DL with no augmentation, DL. We train the model directly from the data without further transformations.
• DL with SVM augmentation, DL + SVM. We used the SVM model trained beforehand to enhance the data. We set a number of observations that we want to enhance and generate random timestamps we use for prediction using SVM. Then we add those artificial values as new observations for training.
• DL with SVM augmentation and random noise, DL + SVM + noise. We follow the same process as in SVM augmentation, but before adding the predictions to the training pool, we add normal noise.
For the SVM we use one input feature, the days passed, and one output feature, the size of the tumor. For DL, we use the gated recurrent units (GRUs;
3.3 Results
As previously mentioned, we evaluate the systems on a series of instantiations depicting various decision support tasks relevant for clinical use. All of the five models were evaluated through multiple metrics (Table 2) on each of the four cell line datasets. In order to evaluate the distribution of the measurement error as a function of the measured volumes of the tumors, the work of
TABLE 2
| Metric | Equation |
|---|---|
| SSE | |
| RMSE | |
| sMAPE | |
| AIC | |
| BIC |
Evaluation metrics for data-driven relation learning systems. We consider N—number of measurements, σ—standard deviation of data, p—number of parameters of the model.
This model shows that when overestimating (ym ≥ y), the measurement error α is subproportional, and when underestimating (ym < y), the obtained error is the same as the measured data points. In our experiments, we consider α = 0.84 and σ = 0.21 as a good trade-off of error penalty and enhancement. We use this measurement error formulation to calculate the typical performance indices (i.e., sum of squared errors [SSE], root mean squared error [RMSE], symmetric mean absolute percentage error [sMAPE]) and goodness-of-fit and parsimony (i.e., Akaike information criterion [AIC] and Bayesian information criterion [BIC]), as shown in Table 2.
3.3.1 Learning Growth Patterns of Preinvasive Breast Cancer
Analyzing tumor infiltration patterns, clinicians can evaluate the evolution of neoplastic processes, for instance, from DCIS to breast cancer. Such an analysis can provide very important benefits, in early detection, in order to (1) increase patient survival, (2) decrease the likelihood for multiple surgeries, and (3) determine the choice of adjuvant versus neoadjuvant chemotherapy. For a full analysis and in-depth discussion of our system’s capabilities for such a task, refer to
As one can see in Table 3, our system overcomes the other approaches on predicting the nonlinear dependency between radius of the breast tumor (R) given the nutrient diffusion penetration length within the breast tissue (L) and ratio of cell apoptosis to proliferation rates (A) from real in vivo histopathologic and morphological data.
TABLE 3
| Evaluation metrics | |||
|---|---|---|---|
| Dataset/system | SSE | RMSE | sMAPE |
| Breast (DCIS), | |||
| Cook et al. | 56.321 | 0.4867 | 0.5901 |
| Weber et al. | 59.879 | 0.5099 | 0.6512 |
| Mandal et al. | 62.346 | 0.5617 | 0.6800 |
| Champion et al. | 58.645 | 0.4721 | 0.6054 |
| Our system | 54.216 | 0.4656 | 0.5734 |
Evaluation of the data-driven relation learning systems.
3.3.2 Learning Unperturbed Tumor Growth Curves Within and Between Cancer Types
In the second task, we evaluated the systems on learning unperturbed (i.e., growth without treatment) tumor growth curves. The choice of different cancer types (i.e., two breast cell lines, lung, and leukemia) is to probe and demonstrate between- and within-tumor-type prediction versatility.
Our system provides overall better accuracy between- and within-tumor-type growth curve prediction, as shown in Table 4 and the summary statistics (depicted in Figure 5). The superior performance is given by the fact that our system can overcome the other approaches when facing incomplete biological descriptions, the diversity of tumor types, and the small size of the data. Interested readers can refer to
TABLE 4
| Evaluation metrics (smaller value is better) | ||||||
|---|---|---|---|---|---|---|
| Dataset/system | SSE | RMSE | sMAPE | AIC | BIC | Rank3 |
| Breast4 cancer | ||||||
| Cook et al. | 7,009.6 | 37.4423 | 1.7088 | 52.3639 | 52.2557 | 2 |
| Weber et al. | 8,004.9 | 44.7350 | 1.7088 | 55.2933 | 55.1310 | 5 |
| Mandal et al. | 7,971.8 | 39.9294 | 1.7088 | 53.2643 | 53.1561 | 4 |
| Champion et al. | 6,639.1 | 40.7403 | 1.4855 | 53.9837 | 53.8215 | 3 |
| Our system | 119.3 | 4.1285 | 0.0768 | 19.8508 | 19.8508 | 1 |
| Breast5 cancer | ||||||
| Cook et al. | 0.2936 | 0.1713 | 0.1437 | −40.5269 | −39.5571 | 4 |
| Weber et al. | 0.2315 | 0.1604 | 0.1437 | −41.3780 | −39.9233 | 2 |
| Mandal et al. | 0.3175 | 0.1782 | 0.1437 | −39.5853 | −38.6155 | 5 |
| Champion et al. | 0.2699 | 0.1732 | 0.1512 | −39.5351 | −38.0804 | 3 |
| Our system | 0.0977 | 0.0902 | 0.0763 | −57.7261 | −57.7261 | 1 |
| Breast6 cancer | ||||||
| Cook et al. | 3.0007 | 0.7071 | 1.0606 | 50.1322 | 51.2887 | 2 |
| Weber et al. | 3.2942 | 0.8116 | 1.6626 | 56.4133 | 55.1915 | 5 |
| Mandal et al. | 3.1908 | 0.7292 | 1.3506 | 53.2643 | 52.5421 | 4 |
| Champion et al. | 3.4772 | 0.8339 | 1.1288 | 53.9837 | 53.7775 | 3 |
| Our system | 0.7668 | 0.3096 | 0.2615 | 19.3208 | 19.1298 | 1 |
| Breast7 cancer | ||||||
| Cook et al. | 45.6031 | 2.3875 | 1.2216 | −40.0084 | −39.9975 | 4 |
| Weber et al. | 56.0738 | 2.8302 | 1.8346 | −41.2345 | −39.1234 | 2 |
| Mandal et al. | 53.2428 | 2.5797 | 1.4816 | −39.5853 | −37.1260 | 5 |
| Champion et al. | 54.7189 | 2.7958 | 1.5086 | −39.1234 | −38.0664 | 3 |
| Our system | 0.2008 | 0.1417 | 0.0364 | −57.1221 | −57.6112 | 1 |
| Lung cancer | ||||||
| Cook et al. | 44.5261 | 2.2243 | 1.5684 | 19.3800 | 20.1758 | 2 |
| Weber et al. | 54.1147 | 2.6008 | 1.5684 | 23.5253 | 24.7190 | 5 |
| Mandal et al. | 53.2475 | 2.4324 | 1.5684 | 21.3476 | 22.1434 | 4 |
| Champion et al. | 50.6671 | 2.5166 | 1.5361 | 22.8012 | 23.9949 | 3 |
| Our system | 3.6903 | 0.5792 | 0.2121 | −12.0140 | −12.0140 | 1 |
| Leukemia | ||||||
| Cook et al. | 223.7271 | 3.2640 | 1.6368 | 56.3235 | 58.5944 | 2 |
| Weber et al. | 273.6770 | 3.6992 | 1.6368 | 62.9585 | 66.3649 | 5 |
| Mandal et al. | 259.9277 | 3.5182 | 1.6368 | 59.7729 | 62.0439 | 4 |
| Champion et al. | 248.5784 | 3.5255 | 1.6001 | 60.7461 | 64.1526 | 3 |
| Our system | 35.2541 | 1.2381 | 0.3232 | 9.8230 | 9.8230 | 1 |
Evaluation of the data-driven relation learning systems on tumor growth curve extraction.
Notes: 3—Calculated as best in 3/5 metrics; 4—MDA-MB-231 cell line; 5—MDA-MB-435 cell line; 6—MCF-7, T47D cell line; 7—LM2-4LUC + cell line.
FIGURE 5

Evaluation of the data-driven relation learning systems on tumor growth: summary statistics.
3.3.3 Extracting Tumor Phenotypic Stage Transitions
The next evaluation task looks at learning the mathematical relations describing the phenotypic transitions of tumors in breast cancer. For this experiment, we considered the study of 17 breast cancer patients in the study by
In this instantiation, we focus on a simplified three-state phenotypic model (i.e., containing P, Q, A states). The transitions among tumor states are stochastic events generated by Poisson processes. Each of the data-driven relation learning systems is fed with time series of raw immunohistochemistry and morphometric data for each of the 17 tumor cases (
FIGURE 6

Learning cancer cells phenotypic states transitions mathematical relations.
Q–A and Q–P state transitions of cancer cells are depicted in Figure 6, where we also present the relation that our system learned. Both in Figure 6 and Table 5, we can see that our system is able to recover the correct underlying mathematical function with respect to ground truth (clinically extracted and modeled Eq. 10 from the study by
TABLE 5
| Evaluation metrics | |||
|---|---|---|---|
| State transition/system | SSE | RMSE | sMAPE |
| Quiescent(Q) to proliferation(P) transition relation | |||
| Cook et al. | 0.820 | 0.240 | 0.190 |
| Weber et al. | 0.865 | 0.294 | 0.196 |
| Mandal et al. | 0.904 | 0.320 | 0.214 |
| Champion et al. | 0.845 | 0.274 | 0.189 |
| Our system | 0.750 | 0.210 | 0.172 |
| Quiescent(Q) to apoptosis(A) transition relation | |||
| Cook et al. | 0.421 | 0.162 | 0.140 |
| Weber et al. | 0.484 | 0.178 | 0.154 |
| Mandal et al. | 0.490 | 0.182 | 0.151 |
| Champion et al. | 0.441 | 0.166 | 0.147 |
| Our system | 0.398 | 0.153 | 0.131 |
Evaluation of the data-driven relation learning systems for extracting phenotypic transitions relations.
Note that none of the evaluated system had prior knowledge of the data distribution or biological assumptions. To have a more detailed overview on the capabilities of our system to capture phenotypic dynamics, refer to
3.3.4 Simultaneously Extracting Drug-Perturbed Tumor Growth and Drug Pharmacokinetics
Chemotherapy use in the neoadjuvant and adjuvant settings generally provides the same long-term outcome (
In the current section, we present the experimental results of all the evaluated systems and consider (1) accuracy in learning the chemotherapy-perturbed tumor growth model and (2) accuracy in learning the pharmacokinetics of the chemotoxic drug (i.e., paclitaxel) dose. For the tumor growth curve extraction, we considered four cell lines of breast cancer (i.e., MDA-MB-231, MDA-MB-435, MCF-7, LM2-LUC + cell lines; Table1). The evaluation results of the systems in the perturbed tumor growth scenario are provided in Figure 7. Note that our system learns the temporal relationships among the quantities fed to the two sides of the system (Figure 3), which can, subsequently, be used to infer one (unavailable) quantity based on the one available. For instance, if the system had learned the change in volume at irregular time points, given a next time point, the system will recover the most plausible volume value—basically accounting for a one-step-ahead prediction. For a longer prediction horizon, one can recurrently apply this process for new predictions and so on.
FIGURE 7

Evaluation of the data-driven relation learning system on perturbed tumor growth: accuracy evaluation. The decrease in the MCF7 dataset is due to a high-dose chemotherapy administration and demonstrates the adaptivity of the methods to cope such abnormal growth behaviors.
Table 6 presents the results using SVM and the different versions of DL. We can see that usually vanilla DL outperforms SVM. DL is a more complex model, as well as uses more input data, so this result is expected. Once we add the augmentation from SVM, the model has a comparable performance to SVM. Our theory is that this is caused by DL learning to imitate SVM instead of real data. Once we add noise to the augmentation, the data become more realistic and usually yield improvements in performance.
TABLE 6
| Evaluation of the deep learning approach | |||||
|---|---|---|---|---|---|
| Dataset | Cancer (cell line) | RMSESVM | RMSEDL | RMSEDL+SVM | RMSEDL+SVM+noise |
| 1 | Breast (MDA-MB-231) | 1.8424 | 1.5382 | 1.7544 | 1.7088 |
| 2 | Breast (MDA-MB-435) | 1.0977 | 1.5990 | 0.9584 | 0.9012 |
| 3 | Breast (MCF-7) | 1.4112 | 1.7295 | 1.3632 | 1.0607 |
| 4 | Breast (LM2-4LUC+) | 1.8945 | 1.8345 | 1.7620 | 1.4816 |
Description of the DL approach inspired by
Note that for all of the evaluation datasets, the best performing DL approach [i.e., inspired by
For the pharmacokinetics learning experiments, we used the data from the computational model of intracellular pharmacokinetics of paclitaxel of
As one can see in Figure 8A, the intracellular concentration kinetics of paclitaxel is highly nonlinear. Our system is able to extract the underlying function describing the data without any assumption about the data and other prior information, opposite to the model from (
FIGURE 8

Learning the pharmacokinetics of the intracellular (A) and extracellular (B) paclitaxel concentration. Data from
Analyzing the extracellular concentration in Figure 8B, we can see that our system extracted the trend and the individual variation of drug concentration after the administration of the drug (i.e., in the first 6 h) and learned an accurate fit without any prior or other biological assumptions. Interestingly, our system captured the fact that the intracellular drug concentration increased linearly with extracellular concentration decrease, as shown in Figure 8.
The overall evaluation of pharmacokinetics learning is given in Table 7.
TABLE 7
| Evaluation metrics | |||
|---|---|---|---|
| Pharmacokinetics data/system | SSE | RMSE | sMAPE |
| Intracellular paclitaxel | |||
| Cook et al. | 0.6234 | 0.2812 | 0.1487 |
| Weber et al. | 0.7212 | 0.3689 | 0.1794 |
| Mandal et al. | 0.6743 | 0.3046 | 0.1602 |
| Champion et al. | 0.6539 | 0.2607 | 0.1500 |
| Our system | 0.5960 | 0.2141 | 0.1403 |
| Extracellular paclitaxel | |||
| Cook et al. | 0.5676 | 0.2341 | 0.1213 |
| Weber et al. | 0.6674 | 0.2891 | 0.1289 |
| Mandal et al. | 0.6128 | 0.2974 | 0.1366 |
| Champion et al. | 0.5790 | 0.2633 | 0.1156 |
| Our system | 0.5484 | 0.2054 | 0.1068 |
Evaluation of the data-driven relation learning systems for pharmacokinetics extraction.
In this series of experiments, all of the systems learned that changes in cell number were represented by changes in volume, which (1) increased with time at low initial total extracellular drug concentrations due to continued cell proliferation and (2) decreased with time at high initial total extracellular drug concentrations due to the antiproliferative and/or cytotoxic drug effects, as reported by
3.3.5 Predicting Tumor Growth/Recession Under Chemotherapy
In the last series of experiments, we used real patient data from the I-SPY 1 TRIAL: ACRIN 6657 (
FIGURE 9

The I-SPY2 trial dataset properties.
As we can observe in Table 8, our system learns a superior fit to the tumor growth data, with respect to the other systems, despite the limited number of samples (i.e., 7 data points for MDA-MD-231 cell line dataset and up to 14 data points for MDA-MD-435 cell line dataset). It is important to note that when analyzing tumor growth functions and response under chemotherapy, we faced the high variability among patients given by the typical constellation of hormone receptor indicators (i.e., HR and HER2neu, which covered the full spectrum of positive and negative values) for positive and negative prognoses. All data-driven learning systems capture such aspects to some extent. Our system learns a superior fit overall the three metrics, capturing the intrinsic impact chemotherapy has upon the tumor growth function, despite the limited number of samples (i.e., 4 data points of the dataset overall evaluation dataset of 20% of patients). An extended evaluation of our system on a broader set of datasets for therapy outcome prediction is given by
TABLE 8
| Evaluation metrics | |||
|---|---|---|---|
| Dataset/model | SSE | RMSE | sMAPE |
| I-SPY2 trial | |||
| Cook et al. | 1.3735 | 1.1439 | 0.1133 |
| Weber et al. | 1.7543 | 1.2005 | 0.2539 |
| Mandal et al. | 2.963 | 1.0963 | 0.7834 |
| Champion et al. | 2.0747 | 1.04100 | 0.1073 |
| Our system | 0.8650 | 0.4650 | 0.0389 |
Evaluation of the data-driven relation learning systems on real patient breast cancer data.
4 Discussion
We complement the quantitative evaluation in the previous section with an analysis of the most important features of all the systems capable to extract mathematical relations in the aforementioned clinical oncology tasks. As the performance evaluation was done in the previous section, we will now focus on other specific comparison terms relevant for the adoption of such systems in clinical practice.
One initial aspect is the design and functionality. Using either distributed representations (
A second aspect refers to the amount of prior information embedded by the designer in the system. It is typical that, depending on the instantiation, a new set of parameters is needed, making the models less flexible. Although less intuitive, the pure mathematical approaches (
A third aspect relevant to the analysis is the stability and robustness of the obtained representation. The representation of the hidden relation (1) can be encoded in a weight matrix
The capability to handle noisy data is an important aspect concerning the applicability in real-world scenarios. Using either computational mechanisms for denoising (
Another relevant feature is the capability to infer (i.e., predict/anticipate) missing quantities once the mathematical relation is learned. The capability to use the learned relations to determine missing quantities is not available in all presented systems, such as the system of
Finally, because of the fact that all methods reencode the real-world values in new representation, it is important to study the capability to decode the learned representation and subsequently measure the precision of the learned representation. Although not explicitly treated in the presented systems, decoding the extracted representations is not trivial. Using a tiled mapping of the input values along the neural network representations, the system of
5 Conclusion
Data-driven approaches to improve decision-making in clinical oncology are now going beyond diagnosis. From early detection of infiltrating tumors to unperturbed tumor growth phenotypic staging, and from pharmacokinetics-dictated therapy planning to treatment outcome, data-driven tools capable of learning hidden correlations in the data are now taking the foreground in mathematical and computational oncology. Our study introduces a novel framework and versatile system capable of learning physical and mathematical relations in heterogeneous oncology data. Together with a lightweight and transparent computational substrate, our system provides human-understandable solutions. This is achieved by capturing the distribution of the data in order to achieve superior fit and prediction capabilities between and within cancer types. Supported by an exhaustive evaluation on in vitro and in vivo data, against state-of-the-art machine learning and DL systems, the proposed system stands out as a promising candidate for clinical adoption. Mathematical and computational oncology is an emerging field where efficient, transparent, and understandable data-driven systems hold the promise of paving the way to individualized therapy. But this can only be achieved by capturing the peculiarities of a patient’s tumor across scales and data types.
Statements
Data availability statement
Publicly available datasets were analyzed in this study. This data can be found here: https://gitlab.com/akii-microlab/chimera/-/tree/master/datasets.
Author contributions
DK designed the research, collected clinical datasets, and performed data analysis of clinical studies used in the experiments. CS developed the source code for the experiments and the analysis. CA designed the research and developed the source code for the experiments.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/frai.2021.713690/full#supplementary-material
Footnotes
1.^A copy of the used datasets along with the study generating them is included in the codebase associated with the manuscript.
2.^Experimental codebase: https://gitlab.com/akii-microlab/math-comp-ml.
3.^https://wiki.cancerimagingarchive.net/display/Public/ISPY1.
References
1
AblerD.BüchlerP.RockneR. C. (2019). “Towards Model-Based Characterization of Biomechanical Tumor Growth Phenotypes,” in Mathematical and Computational Oncology. Editors BebisG.BenosT.ChenK.JahnK.LimaE. (Cham: Springer International Publishing), 75–86. 10.1007/978-3-030-35210-3_6
2
AntonelliA.NoortW. A.JaquesJ.de BoerB.de Jong-KorlaarR.Brouwers-VosA. Z.et al (2016). Establishing Human Leukemia Xenograft Mouse Models by Implanting Human Bone Marrow-like Scaffold-Based Niches. Blood J. Am. Soc. Hematol.128, 2949–2959. 10.1182/blood-2016-05-719021
3
AxenieC.KurzD. (2020a). “Chimera: Combining Mechanistic Models and Machine Learning for Personalized Chemotherapy and Surgery Sequencing in Breast Cancer,” in International Symposium on Mathematical and Computational Oncology (Springer), 13–24. 10.1007/978-3-030-64511-3_2
4
AxenieC.KurzD. (2021). “Glueck: Growth Pattern Learning for Unsupervised Extraction of Cancer Kinetics,” in Machine Learning and Knowledge Discovery in Databases. Applied Data Science and Demo Track: European Conference, ECML PKDD 2020, Ghent, Belgium, September 14–18, 2020, Proceedings, Part V (Springer International Publishing), 171–186. 10.1007/978-3-030-67670-4_11
5
AxenieC.KurzD. (2020b). “Princess: Prediction of Individual Breast Cancer Evolution to Surgical Size,” in 2020 IEEE 33rd International Symposium on Computer-Based Medical Systems (CBMS) (IEEE), 457–462. 10.1109/cbms49503.2020.00093
6
AxenieC.KurzD. (2020c). “Tumor Characterization Using Unsupervised Learning of Mathematical Relations within Breast Cancer Data,” in International Conference on Artificial Neural Networks (Springer), 838–849. 10.1007/978-3-030-61616-8_67
7
Ben-ShmuelA.BiberG.Barda-SaadM. (2020). Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?. Front. Immunol.11, 275. 10.3389/fimmu.2020.00275
8
BenzekryS.LamontC.WeremowiczJ.BeheshtiA.HlatkyL.HahnfeldtP. (2019). Tumor Growth Kinetics of Subcutaneously Implanted Lewis Lung Carcinoma Cells. Zenodo, 3572401. 10.5281/zenodo.3572401
9
BenzekryS. (2020). Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology. Clin. Pharmacol. Ther.108, 471–486. 10.1002/cpt.1951
10
BenzekryS.LamontC.BeheshtiA.TraczA.EbosJ. M. L.HlatkyL.et al (2014). Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. Plos Comput. Biol.10 (8), e1003800. 10.1371/journal.pcbi.1003800
11
BergJ.NyströmK. (2019). Data-driven Discovery of Pdes in Complex Datasets. J. Comput. Phys.384, 239–252. 10.1016/j.jcp.2019.01.036
12
BrentR. P. (2013). Algorithms for Minimization without Derivatives. Chelmsford, United States: Courier Corporation.
13
ChampionK.LuschB.KutzJ. N.BruntonS. L. (2019). Data-driven Discovery of Coordinates and Governing Equations. Proc. Natl. Acad. Sci. USA116, 22445–22451. 10.1073/pnas.1906995116
14
ChamseddineI. M.RejniakK. A. (2020). Hybrid Modeling Frameworks of Tumor Development and Treatment. Wiley Interdiscip. Rev. Syst. Biol. Med.12, e1461. 10.1002/wsbm.1461
15
ChenN.LiY.YeY.PalmisanoM.ChopraR.ZhouS. (2014). Pharmacokinetics and Pharmacodynamics of Nab ‐paclitaxel in Patients with Solid Tumors: Disposition Kinetics and Pharmacology Distinct from Solvent‐based Paclitaxel. J. Clin. Pharmacol.54, 1097–1107. 10.1002/jcph.304
16
ChenZ.HaykinS.EggermontJ. J.BeckerS. (2008). Correlative Learning: A Basis for Brain and Adaptive Systems, Vol. 49. John Wiley & Sons.
17
ChungJ.GulcehreC.ChoK.BengioY. (2014). Empirical Evaluation of Gated Recurrent Neural Networks on Sequence Modeling. arXiv preprint arXiv:1412.3555.
18
ComenE.GilewskiT. A.NortonL. (2016). Tumor Growth Kinetics. Hoboken, United States: Holland-Frei Cancer Medicine, 1–11.
19
CookM.JugF.KrautzC.StegerA. (2010). “Unsupervised Learning of Relations,” in International Conference on Artificial Neural Networks (Springer), 164–173. 10.1007/978-3-642-15819-3_21
20
CornishA. J.MarkowetzF. (2014). Santa: Quantifying the Functional Content of Molecular Networks. Plos Comput. Biol.10, e1003808. 10.1371/journal.pcbi.1003808
21
CristiniV.KoayE.WangZ. (2017). An Introduction to Physical Oncology: How Mechanistic Mathematical Modeling Can Improve Cancer Therapy Outcomes. Boca Raton: CRC Press.
22
de SilvaB. M.HigdonD. M.BruntonS. L.KutzJ. N. (2020). Discovery of Physics from Data: Universal Laws and Discrepancies. Front. Artif. Intell.3, 25. 10.3389/frai.2020.00025
23
EdgertonM. E.ChuangY.-L.MacklinP.YangW.BearerE. L.CristiniV. (2011). A Novel, Patient-specific Mathematical Pathology Approach for Assessment of Surgical Volume: Application to Ductal Carcinomain Situof the Breast. Anal. Cell. Pathol.34, 247–263. 10.1155/2011/803816
24
GaddyT. D.WuQ.ArnheimA. D.FinleyS. D. (2017). Mechanistic Modeling Quantifies the Influence of Tumor Growth Kinetics on the Response to Anti-angiogenic Treatment. Plos Comput. Biol.13, e1005874. 10.1371/journal.pcbi.1005874
25
GerleeP. (2013). The Model Muddle: in Search of Tumor Growth Laws. Cancer Res.73, 2407–2411. 10.1158/0008-5472.can-12-4355
26
Griffon-EtienneG.BoucherY.BrekkenC.SuitH. D.JainR. K. (1999). Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications. Cancer Res.59, 3776–3782. 10.1158/0008-5472
27
JansenT.GeleijnseG.Van MaarenM.HendriksM. P.Ten TeijeA.Moncada-TorresA. (2020). “Machine Learning Explainability in Breast Cancer Survival,” in 30th Medical Informatics Europe Conference, MIE 2020 (Amsterdam, Netherlands: IOS Press), 307–311.
28
KohonenT. (1982). Self-organized Formation of Topologically Correct Feature Maps. Biol. Cybern.43, 59–69. 10.1007/bf00337288
29
KondylakisH.AxenieC.BastolaD.KatehakisD. G.KouroubaliA.KurzD.et al (2020). Status and Recommendations of Technological and Data-Driven Innovations in Cancer Care: Focus Group Study. J. Med. Internet Res.22, e22034. 10.2196/22034
30
KuhH. J.JangS. H.WientjesM. G.AuJ. L. (2000). Computational Model of Intracellular Pharmacokinetics of Paclitaxel. J. Pharmacol. Exp. Ther.293, 761–770.
31
KurzD.AxenieC. (2020). “Perfecto: Prediction of Extended Response and Growth Functions for Estimating Chemotherapy Outcomes in Breast Cancer,” in 2020 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) (IEEE), 609–614. 10.1109/bibm49941.2020.9313551
32
LamyJ.-B.SekarB.GuezennecG.BouaudJ.SéroussiB. (2019). Explainable Artificial Intelligence for Breast Cancer: A Visual Case-Based Reasoning Approach. Artif. intelligence Med.94, 42–53. 10.1016/j.artmed.2019.01.001
33
LongZ.LuY.MaX.DongB. (2018). “Pde-net: Learning Pdes from Data,” in International Conference on Machine Learning (Brookline: Microtome Publishing), 3208–3216.
34
MacklinP.EdgertonM. E.ThompsonA. M.CristiniV. (2012). Patient-calibrated Agent-Based Modelling of Ductal Carcinoma In Situ (Dcis): from Microscopic Measurements to Macroscopic Predictions of Clinical Progression. J. Theor. Biol.301, 122–140. 10.1016/j.jtbi.2012.02.002
35
MandalA.CichockiA. (2013). Non-linear Canonical Correlation Analysis Using Alpha-Beta Divergence. Entropy15, 2788–2804. 10.3390/e15072788
36
MarkowetzF.TroyanskayaO. G. (2007). Computational Identification of Cellular Networks and Pathways. Mol. Biosyst.3, 478–482. 10.1039/b617014p
37
MastriM.TraczA.EbosJ. M. (2019). Population Modeling of Tumor Growth Curves and the Reduced Gompertz Model Improve Prediction of the Age of Experimental Tumors. PLoS Comput. Biol.16, e1007178. 10.1371/journal.pcbi.1007178
38
NathansonS. D.NelsonL. (1994). Interstitial Fluid Pressure in Breast Cancer, Benign Breast Conditions, and Breast Parenchyma. Ann. Surg. Oncol.1, 333–338. 10.1007/bf03187139
39
NiaH. T.LiuH.SeanoG.DattaM.JonesD.RahbariN.et al (2016). Solid Stress and Elastic Energy as Measures of Tumour Mechanopathology. Nat. Biomed. Eng.1, 1–11. 10.1038/s41551-016-0004
40
NiaH. T.MunnL. L.JainR. K. (2020). Physical Traits of Cancer. Science370, eaaz0868. 10.1126/science.aaz0868
41
RaissiM. (2018). Deep Hidden Physics Models: Deep Learning of Nonlinear Partial Differential Equations. J. Machine Learn. Res.19, 932–955.
42
RodallecA.GiacomettiS.CiccoliniJ.FanciullinoR. (2019). Tumor Growth Kinetics of Human MDA-MB-231 Cells Transfected with dTomato Lentivirus. Springer. 10.5281/zenodo.3593919
43
RolandC. L.DineenS. P.LynnK. D.SullivanL. A.DellingerM. T.SadeghL.et al (2009). Inhibition of Vascular Endothelial Growth Factor Reduces Angiogenesis and Modulates Immune Cell Infiltration of Orthotopic Breast Cancer Xenografts. Mol. Cancer Ther.8, 1761–1771. 10.1158/1535-7163.MCT-09-0280
44
RouvièreO.MelodelimaC.Hoang DinhA.BratanF.PagnouxG.SanzaloneT.et al (2017). Stiffness of Benign and Malignant Prostate Tissue Measured by Shear-Wave Elastography: a Preliminary Study. Eur. Radiol.27, 1858–1866. 10.1007/s00330-016-4534-9
45
SarapataE. A.de PillisL. G. (2014). A Comparison and Catalog of Intrinsic Tumor Growth Models. Bull. Math. Biol.76, 2010–2024. 10.1007/s11538-014-9986-y
46
SchaefferH. (2017). Learning Partial Differential Equations via Data Discovery and Sparse Optimization. Proc. R. Soc. A.473, 20160446. 10.1098/rspa.2016.0446
47
Simpson-HerrenL.LloydH. H. (1970). Kinetic Parameters and Growth Curves for Experimental Tumor Systems. Cancer Chemother. Rep.54, 143–174.
48
StageT. B.BergmannT. K.KroetzD. L. (2018). Clinical Pharmacokinetics of Paclitaxel Monotherapy: an Updated Literature Review. Clin. Pharmacokinet.57, 7–19. 10.1007/s40262-017-0563-z
49
TanG.KasuyaH.SahinT. T.YamamuraK.WuZ.KoideY.et al (2015). Combination Therapy of Oncolytic Herpes Simplex Virus Hf10 and Bevacizumab against Experimental Model of Human Breast Carcinoma Xenograft. Int. J. Cancer136, 1718–1730. 10.1002/ijc.29163
50
UzhachenkoR. V.ShankerA. (2019). Cd8+ T Lymphocyte and Nk Cell Network: Circuitry in the Cytotoxic Domain of Immunity. Front. Immunol.10, 1906. 10.3389/fimmu.2019.01906
51
Van de WielM.DockxY.Van den WyngaertT.StroobantsS.TjalmaW. A. A.HuizingM. T. (2017). Neoadjuvant Systemic Therapy in Breast Cancer: Challenges and Uncertainties. Eur. J. Obstet. Gynecol. Reprod. Biol.210, 144–156. 10.1016/j.ejogrb.2016.12.014
52
VolkL. D.FlisterM. J.ChihadeD.DesaiN.TrieuV.RanS. (2011). Synergy of Nab-Paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases. Neoplasia13, 327–IN14. 10.1593/neo.101490
53
WeberC.WermterS. (2007). A Self-Organizing Map of Sigma-Pi Units. Neurocomputing70, 2552–2560. 10.1016/j.neucom.2006.05.014
54
WernerB.ScottJ. G.SottorivaA.AndersonA. R. A.TraulsenA.AltrockP. M. (2016). The Cancer Stem Cell Fraction in Hierarchically Organized Tumors Can Be Estimated Using Mathematical Modeling and Patient-specific Treatment Trajectories. Cancer Res.76, 1705–1713. 10.1158/0008-5472.can-15-2069
55
WhiteF. M.GatenbyR. A.FischbachC. (2019). The Physics of Cancer. Cancer Res.79, 2107–2110. 10.1158/0008-5472.can-18-3937
56
YeeD.DeMicheleA. M.YauC.IsaacsC.SymmansW. F.AlbainK. S.et al (2020). Association of Event-free and Distant Recurrence–free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-Up Analysis for the I-Spy2 Adaptively Randomized Clinical Trial. Chicago: JAMA.
57
ZaheedM.WilckenN.WillsonM. L.O’ConnellD. L.GoodwinA. (2019). Sequencing of Anthracyclines and Taxanes in Neoadjuvant and Adjuvant Therapy for Early Breast Cancer. Hoboken: John Wiley & Sons Ltd.
Summary
Keywords
mathematical oncology, machine learning, mechanistic modeling, data-driven predictions, clinical data, decision support system
Citation
Kurz D, Sánchez CS and Axenie C (2021) Data-Driven Discovery of Mathematical and Physical Relations in Oncology Data Using Human-Understandable Machine Learning. Front. Artif. Intell. 4:713690. doi: 10.3389/frai.2021.713690
Received
23 May 2021
Accepted
08 October 2021
Published
25 November 2021
Volume
4 - 2021
Edited by
George Bebis, University of Nevada, Reno, United States
Reviewed by
Chang Chen, University of Chicago, United States
Tin Nguyen, University of Nevada, Reno, United States
Sokratis Makrogiannis, Delaware State University, United States
Updates

Check for updates
Copyright
© 2021 Kurz, Sánchez and Axenie.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cristian Axenie, cristian.axenie@audi-konfuzius-institut-ingolstadt.de
† These authors have contributed equally to the work
This article was submitted to Medicine and Public Health, a section of the journal Frontiers in Artificial Intelligence
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.